C970 Stock Chart & Stats
€5.16
€0.00(0.00%)
At close: 4:00 PM EDT
€5.16
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€5.16 - €31.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.14M
Enterprise Value€11.51M
Total Cash (Recent Filing)€3.65M
Total Debt (Recent Filing)€1.80M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Nov 05, 2026EPS Estimate
-1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-26.72
Shares Outstanding7,448,705
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.33
Price to Sales (P/S)10.83
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.60Price Target Upside-30.32% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-10.82
Revenue Forecast (FY)€491.83K
Bulls Say, Bears Say
Bulls Say
TB Regulatory ProgressThe completed clinical study and CDSCO submission advance Co-Diagnostics’ TB program toward potential commercialization in India. Strong reported performance across multiple batches supports regulatory credibility and could create a durable international growth avenue if clearance is obtained.
PCR Platform ExpansionExpansion beyond respiratory swab testing, together with international commercialization and manufacturing partnerships, broadens the potential use of the Co-Dx PCR platform. These initiatives can support market access and localized scale across infectious-disease applications over time.
Lower Operating ExpensesThe reduction in operating expenses and improvement in adjusted EBITDA loss indicate progress in controlling the cost base. Sustained discipline could extend available resources and improve operating leverage if regulatory milestones eventually translate into recurring commercial revenue.
Bears Say
Revenue And Margin CollapseThe severe revenue contraction leaves the company with a very small commercial base relative to its development effort. Large losses and an approximately 8% TTM gross margin indicate that current sales do not yet support the cost structure, making recovery dependent on successful commercialization.
Persistent Cash BurnPersistent operating and free-cash-flow deficits are consuming the liquidity needed to fund regulatory, clinical and commercial programs. The sharp cash decline raises continuing funding requirements, while dependence on financing can constrain strategic flexibility and increase execution risk.
Shrinking Capital BaseThe substantial erosion of equity and assets reflects the cumulative impact of sustained losses and cash use. A smaller capital cushion reduces resilience, limits internally funded investment capacity, and leaves the company less able to absorb delays in regulatory approval or commercial rollout.
Co-Diagnostics News
C970 FAQ
What was Co-Diagnostics Inc’s price range in the past 12 months?
Co-Diagnostics Inc lowest stock price was €5.16 and its highest was €31.20 in the past 12 months.
What is Co-Diagnostics Inc’s market cap?
Co-Diagnostics Inc’s market cap is €3.14M.
When is Co-Diagnostics Inc’s upcoming earnings report date?
Co-Diagnostics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 8 days.
How were Co-Diagnostics Inc’s earnings last quarter?
Co-Diagnostics Inc released its earnings results on Aug 13, 2026. The company reported -€1.312 earnings per share for the quarter.
Is Co-Diagnostics Inc overvalued?
According to Wall Street analysts Co-Diagnostics Inc’s price is currently Overvalued.
Does Co-Diagnostics Inc pay dividends?
Co-Diagnostics Inc does not currently pay dividends.
What is Co-Diagnostics Inc’s EPS estimate?
Co-Diagnostics Inc’s EPS estimate is -1.12.
How many shares outstanding does Co-Diagnostics Inc have?
Co-Diagnostics Inc has 7,448,705 shares outstanding.
What happened to Co-Diagnostics Inc’s price movement after its last earnings report?
Co-Diagnostics Inc reported an EPS of -€1.312 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Co-Diagnostics Inc?
Currently, no hedge funds are holding shares in DE:C970
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Co-Diagnostics Inc
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
C970 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful operational and regulatory progress — including a dual FDA submission for an upper respiratory multiplex assay, >1,400-patient clinical enrollment, >10,000 analytical PCR runs, TB program advancement toward ERPD, a blood-based Ebola proof-of-concept, strengthened international manufacturing partnerships, and reduced operating expenses that improved net loss and adjusted EBITDA. However, these positives are counterbalanced by a very low revenue base ($166K), a steep decline in cash to $3.6M (≈70% drop), continued operating losses, and materially reduced total assets. While execution milestones materially de-risk the technology and regulatory path, the company faces near-term liquidity and commercialization scaling risks.View all DE:C970 earnings summariesC970 Stock 12 Month Forecast
Average Price Target
€3.60
▼(-30.32% Downside)
Technical Analysis
Sintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Allurion Technologies
―
Heart Test Laboratories, Inc.
―